Jiangxi Fushine Pharmaceutical Management
Management criteria checks 3/4
Jiangxi Fushine Pharmaceutical's CEO is Jian Hua Bao, appointed in Apr 2022, has a tenure of 2.75 years. directly owns 20.12% of the company’s shares, worth CN¥873.70M. The average tenure of the management team and the board of directors is 3 years and 6.4 years respectively.
Key information
Jian Hua Bao
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.8yrs |
| CEO ownership | 20.1% |
| Management average tenure | 3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Dec 23
Does Jiangxi Fushine Pharmaceutical (SZSE:300497) Have A Healthy Balance Sheet?
Dec 02There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 28% Price Jump
Oct 04Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?
Jun 12What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You
May 06Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry
Feb 27CEO
Jian Hua Bao (47 yo)
2.8yrs
Tenure
CN¥1,249,100
Compensation
Mr. Jian Hua Bao is GM & Chairman of Jiangxi Fushine Pharmaceutical Co., Ltd. from April 2022 and serves as Chairman since August 25, 2012.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 2.8yrs | CN¥1.25m | 20.12% CN¥ 873.7m | |
| Financial Director | 2.8yrs | CN¥418.50k | 0.0088% CN¥ 383.8k | |
| Deputy GM & Secretary of the Board of Directors | 2.8yrs | CN¥365.20k | 0.0066% CN¥ 285.2k | |
| Deputy General Manager | 12.4yrs | CN¥533.30k | 0.060% CN¥ 2.6m | |
| Deputy General Manager | 8.8yrs | CN¥562.50k | 0.068% CN¥ 3.0m | |
| Deputy General Manager | 5.3yrs | CN¥641.90k | 0.033% CN¥ 1.4m | |
| Deputy General Manager | 3yrs | CN¥635.70k | 0.0073% CN¥ 316.1k | |
| Deputy General Manager | 1.8yrs | CN¥517.80k | 0.031% CN¥ 1.3m | |
| Manager of the Sales Department & Supervisor | 3yrs | no data | no data |
3.0yrs
Average Tenure
46yo
Average Age
Experienced Management: 300497's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman | 12.4yrs | CN¥1.25m | 20.12% CN¥ 873.7m | |
| Manager of the Sales Department & Supervisor | 12.4yrs | no data | no data | |
| Independent Director | 3.3yrs | CN¥119.00k | no data | |
| Chairman of the Supervisory Board | 12.4yrs | no data | no data | |
| Director | 12.4yrs | CN¥482.30k | 0.045% CN¥ 1.9m | |
| Supervisor | 6.4yrs | no data | no data | |
| Director | 4.9yrs | CN¥634.10k | 0.65% CN¥ 28.4m | |
| Vice Chairman | 1.9yrs | CN¥989.20k | 0.044% CN¥ 1.9m | |
| Independent Director | 1.1yrs | CN¥1.80k | no data |
6.4yrs
Average Tenure
51yo
Average Age
Experienced Board: 300497's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 10:12 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangxi Fushine Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Andy Liu | China Stock Investment Research Co. Ltd. (GZ500..com) |